Synthetic Genomics, New England Biolabs Partner to Commercialize DNA Assembly Product | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic Genomics and New England Biolabs announced on Tuesday a non-exclusive licensing agreement for the commercialization of the Gibson Assembly Master Mix.

The deal calls for NEB to commercialize the product, which is based on the Gibson Assembly method, developed by Daniel Gibson and colleagues at the J. Craig Venter Institute as part of a program sponsored by Synthetic Genomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.